#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Treatment of COPD in Individuals with Alpha-1 Antitrypsin Deficiency

A mutation in the gene for alpha-1 antitrypsin (AAT), leading to its deficiency (AATD), causes progressive irreversible destruction of lung tissue. Patients develop chronic obstructive pulmonary disease (COPD) and early emphysema. Several studies evaluating COPD treatment have excluded patients with AATD. The aim of the following systematic literature review was to find and analyze works that include patients with concurrent COPD and AATD and summarize key findings that may form the basis for treatment decisions.
Source: Deficiency of Alpha-1-Antitrypsin 6. 12. 2021

News Importance of pH in Care for Stoma Patients

Maintaining good quality peristomal skin and preventing complications related to the stoma site are integral parts of comprehensive care for patients with stomas. The pH of the skin also plays an important role in this issue, as it can significantly affect the condition of the skin, the development of complications, the quality of life of patients, and consequently impact the economic aspect of stoma care.
Source: Ostomy 19. 3. 2020

News Cannabidiol as a way to reduce anxiety in patients with Parkinson's disease?

A recent study by Brazilian authors examined the effects of cannabidiol on tremors and anxiety in patients with Parkinson's disease. Could it represent a promising modality in this indication?
Source: 27. 5. 2020

News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis

The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.
Source: Psoriasis 16. 5. 2024

News Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID – Available Efficacy and Safety Data

The prevalence of primary immunodeficiencies (PID) is estimated at 1:10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).
Source: Primary and Secondary Immunodeficiencies 3. 4. 2023

News How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?

In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing skeletal events in patients with multiple myeloma or solid tumors (excluding breast and prostate cancer) and bone metastases was evaluated. An ad hoc analysis of this study then involved only a subgroup of patients with solid tumors.
Source: Prevention of Bone Events 12. 9. 2022

News Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results

The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.
Source: Psoriasis 6. 5. 2022

News Repeated Episodes of Respiratory Failure Due to Undiagnosed AAT Deficiency – Case Report

The case report from authors in Naples shows that alpha-1-antitrypsin deficiency (AATD) should be considered when respiratory symptoms occur at any age. It also illustrates the diagnostic procedure in such cases and confirms the effectiveness of subsequently initiated therapy.
Source: Deficiency of Alpha-1-Antitrypsin 14. 11. 2022

News Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?

The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of moderately to severely active ulcerative colitis (UC). Its efficacy and safety in this indication have previously been investigated in randomized placebo-controlled trials. However, the study discussed below examined the drug's impact on the endoscopic and histological progression of the disease and fecal calprotectin levels.
Source: Intestinal Inflammations 20. 9. 2023

News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.
Source: Intestinal Inflammations 21. 8. 2022

News Physical Activity in Young Men with Hemophilia A

What may influence the inclusion of physical activity in the lifestyle of individuals with hemophilia? This was the focus of a Norwegian study published in the journal Haemophilia.
Source: Hemophilia with Movement 6. 10. 2023

News Risk of Subsequent Fractures in Postmenopausal Women After Initial Fracture

Osteoporosis is associated with an increased risk of fractures. The prospective analysis presented below examined the risk of subsequent fractures in postmenopausal women after an initial fracture depending on its location.
Source: Osteoporosis – Trends in Sequential Therapy 4. 9. 2023

News Thromboprophylaxis in Generalized Pancreatic Cancer

Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
Source: Thromboprophylaxis 28. 5. 2021

News How did alemtuzumab fare in real clinical practice?

A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?
Source: Multiple Sclerosis 11. 6. 2021

News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice

Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
Source: Amyloidosis 14. 6. 2023

News Morning Myopic Shift and Glare in Patients with Advanced Fuchs Endothelial Corneal Dystrophy

A newly published study by a German team analyzes the morning and afternoon differences in various parameters in patients with Fuchs endothelial corneal dystrophy to determine which of them contribute to subjective visual difficulties in the morning.
Source: Glaucoma 8. 6. 2020

News How do patients perceive the treatment of ITP with romiplostim?

Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Source: Immune Thrombocytopenia 15. 4. 2024

News Is long-term treatment with ixekizumab sufficiently safe?

Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
Source: Biological Treatment 8. 11. 2021

News When to Initiate Dabigatran Therapy in Patients with Atrial Fibrillation After First Ischemic Stroke?

After a cardioembolic ischemic stroke (iCMP), approximately 5% of patients experience a recurrence within the first 14 days without anticoagulant therapy. The aim of the retrospective observational study presented below was to evaluate the optimal timing of initiating dabigatran anticoagulant therapy with respect to the risk of intracerebral hemorrhage.
Source: Anticoagulant Treatment 21. 7. 2020

News Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in methods for monitoring hemophilic arthropathy and identifying it in its early stages. In addition to classical X-rays, clinical scoring systems, and the gold standard of magnetic resonance imaging (MRI), the so-called POCUS – point-of-care ultrasound – has emerged as a quick and reliable method for assessing joint health. Potential biomarkers for osteochondral damage and synovial proliferation specific to hemophilia or for detecting joint bleeding are also being investigated, though their routine use is not anticipated in the near future.
Source: Hemophilia 10. 6. 2024

News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients

Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.
Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021

News HAE in the Otolaryngologist's Office: How to Handle a Laryngeal Attack?

Hereditary angioedema (HAE) can be encountered in emergency rooms and specialist offices. Patients with this rare disorder are often misdiagnosed with a more common condition, and they may learn their correct diagnosis only after many years. This is because HAE manifests with a combination of symptoms that are typical of various other diseases. What should pediatricians, otorhinolaryngologists, and gastroenterologists be aware of? Providing better understanding of HAE symptoms from different specializations' perspectives and emphasizing the importance of interdisciplinary collaboration for accurate diagnosis and patient care was the focus of a professional webinar we have summarized for you.
Source: Hereditary Angioedema 19. 11. 2021

Journal articles Anaesthesia for minor surgery in the early postpartum period – Czech and Slovak prospective national surveys

Author of the article: P. Tourač, J. Bláha, P. Nosková, R. Klozová, D. Seidlová, M. Grochová, M. Kosinová, J. Jarkovský, H. Zelinková, D. Schwarz, M. Svoboda, S. Richterová, O. Smékalová, B. Zaoralová, Z. Mrozek, Z. Krupková, L. Večeřa, H. Ivanková, A. Magyarová, J. Šimonová, J. Firment Source: Anesteziologie a intenzivní medicína | 2/2019 13. 5. 2019

News Detection of von Willebrand Disease

Von Willebrand disease (vWD) is an autosomal hereditary bleeding disorder. Its detection and diagnosis require several steps, including the initial suspicion of the presence of this disease.
Source: Von Willebrand Disease 23. 3. 2021

News The Future and Prospects of Type 2 Diabetes Therapy: Can We Fully Cure It with Endoscopy or Genetics?

Diabetes mellitus (DM) cannot be cured, but it can be successfully treated... Will we rewrite this textbook fact passed down for years in the future? Will we be able to completely cure type 2 diabetes mellitus (T2DM) one day? The Prague Institute for Clinical and Experimental Medicine (IKEM) sees endoscopic procedures as one of the promising paths and is preparing to test this groundbreaking method of therapy.
Source: Modern Treatment of Diabetes 6. 5. 2021

1 14 15 16 17 18 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#